Back to Speakers

Andrew Simpson earned his Ph.D. in 1980 at the National Institute for Medical Research, Mill Hill, London in the Division of Parasitology and subsequently spent two years at the National Institutes of Health, Bethesda Maryland before returning to Mill Hill where he was a member of the scientific staff until 1990. In 1990, Dr. Simpson moved to Brazil where he continued his research into schistosomiasis and other parasitic diseases while working at the Centro de Pesquisas René Rachou of the Fundação Oswaldo Cruz in Belo Horizonte until joining the Ludwig Institute for Cancer Research in São Paulo in 1995. At LICR he extended his research interests into genomics and led the FAPESP and national genome projects between 1997 and 2002 that sequenced the genomes of bacteria of local interest as well as contributing significantly to the identification of human genes expressed in cancer. In 2002, Dr Simpson transferred to the Ludwig Institute’s office in New York and eventually became LICR Scientific Director in 2007 leading the internationally renowned not for profit research and biotechnology institute for five years. In 2012, Dr. Simpson left LICR and moved back to Brazil to take up the position of Scientific Director of the Brazilian startup biotechnology company Orygen. Orygen, jointly owned by the major Brazilian pharmaceutical companies Biolab and Eurofarm, is currently being structured to develop, produce and commercialize therapeutic monoclonal antibodies and vaccines.